Please assess the completion status of the following clinical trial:

Trial Title: Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained from the patient.~2. Participants must be ≥18 years of age.~3. Morphologically confirmed diagnosis of non-Hodgkin's lymphoma (NHL).~4. At least a single measureable tumor mass (long axis \> 1.5 cm).~5. An FDG-PET positive baseline scan.~   a. A positive scan is defined per revised Cheson criteria as focal or diffuse FDG uptake above background in a location incompatible with normal anatomy or physiology, without a specific standardized uptake value cutoff.~6. Disease that has relapsed after administration of primary therapy that included:~   1. Rituximab and~  2. CHOP, EPOCH, bendamustine or similar chemotherapy or subsequent salvage regimen.~   Note: Relapse is defined as progression after a complete response to therapy or radiographic evidence of active disease after a partial response or stable disease.~7. Have received three or fewer complete courses of systemic cytotoxic regimens. Note: Rituximab (alone or in combination with cytotoxic chemotherapy) is not considered a cytotoxic regimen.~8. No previous exposure to PNT2258.~9. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~10. Have discontinued all prior anti-cancer therapies for at least 21 days; biologic therapy for at least 4 half-lives of the drug(s); radio-immunotherapy (10 weeks); autologous stem cell transplantation (SCT) (3 months) and must be at a stable baseline regarding any acute toxicity associated with prior therapy.~11. Adequate organ function including:~    1. Hematologic Function: absolute neutrophil count (ANC) ≥ 1.5 x 109/L prior to treatment. Platelets ≥ 100 x 109/L.~   2. Hepatic: Total Bilirubin ≤ 1.5 x ULN and serum transaminase levels ≤ 2.5 x upper limits of normal (ULN).~   3. Renal: Serum creatinine ≤2 x ULN or creatinine clearance ≥ 60 mL/min/1.73 m2 for subjects with serum creatinine levels above 2x ULN.~Exclusion Criteria:~1. Candidates for HDT and autologous SCT. Note: Patients who progressed \> 3 months after high-dose therapy (HDT)/SCT are eligible.~2. Concurrent malignancies requiring treatment.~3. Symptomatic central nervous system (CNS) or leptomeningeal involvement of lymphoma.~4. Concurrent serious medical conditions (as determined by the Principal Investigator) including, but not limited to, HIV-associated lymphoma; active bacterial, fungal or viral infections.~5. Signs and symptoms of heart failure characterized as greater than New York Heart Association (NYHA) Class I.~6. History of myocardial infarct or prolonged corrected QT (QTc) interval (\>450 milliseconds (msecs) for males or \>470 msecs for females) or other significant cardiac abnormalities.~7. Women who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PNT2258 (Type: EXPERIMENTAL): PNT2258 120 mg/m2 will be administered as a 2-hour intravenous infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete